Journal
PSYCHOPHARMACOLOGY
Volume 212, Issue 2, Pages 181-191Publisher
SPRINGER
DOI: 10.1007/s00213-010-1943-3
Keywords
Phosphodiesterase-4 (PDE4); Rolipram; beta-Amyloid peptide (A beta); Alzheimer's disease; Memory; CREB
Categories
Funding
- National Institute of Aging [AG031687]
- NARSAD Young Investigator Awards
- National Natural Science Foundation of China [30672453, 30973518]
- Guangdong Natural Science Foundation, China [7117782]
Ask authors/readers for more resources
Cyclic AMP signaling plays an important role in memory loss associated with Alzheimer's disease (AD). However, little is known about whether inhibition of phosphodiesterase-4 (PDE4), which increases intracellular cAMP, reverses beta-amyloid peptide (A beta)-induced memory deficits. Experiments were performed to demonstrate the effect of the PDE4 inhibitor rolipram on memory impairment produced by A beta 1-40 (A beta 40) or its core fragment A beta 25-35. We tested memory using Morris water-maze and passive avoidance tasks and examined expression of phosphorylated cAMP response-element binding protein (pCREB) in the hippocampus in rats treated with A beta 25-35 or A beta 40 into bilateral CA1 subregions, with or without rolipram administration. A beta 25-35 (10 mu g/side) increased escape latency during acquisition training and decreased swimming time and distance in the target quadrant in the water-maze probe trial; it also decreased 24-h retention in the passive avoidance paradigm. All these were reversed by chronic administration of rolipram (0.5 mg/kg). Similarly, A beta 40 (4 mu g/side) produced memory impairment, as demonstrated by decreased retention in passive avoidance; this was also reversed by repeated treatment with rolipram. In addition, rolipram blocked extinction of memory during the 32-day testing period in the passive avoidance test. Further, A beta 40 decreased pCREB expression in the hippocampus, which was also reversed by rolipram; the changes in pCREB were highly correlated with those in memory. These results suggest that the PDE4 inhibitor rolipram reverses cognitive deficits associated with AD most likely via increased cAMP/CREB signaling in the hippocampus; PDE4 could be a target for drugs that improve cognition in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available